High PSALow volume diseaseRarely, patients with prostate cancer (PC) present with Prostate-Specific Antigen (PSA) scores >20ng/mL but otherwise very low-risk disease. Oncologists debate whether malignancies in these patients behave more comparably to low-risk or high-risk disease. Our objective ...
Prostate-specific antigen (PSA) is the tumor marker most widely used in conjunction with digital rectal examination (DRE) for the early detection of prostate cancer (PCa). Due to its limitations, especially the high rate of false positive (FP) results, PSA screening of transplant candidates is...
Prostate-specific antigen (PSA) is the tumor marker most widely used in conjunction with digital rectal examination (DRE) for the early detection of prostate cancer (PCa). Due to its limitations, especially the high rate of false positive (FP) results, PSA screening of transplant candidates is...
Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral ... Purpose;Prostate cancer (PCa) prevention remains an appealing strategy for the reduction of overtreatment and secondary adverse effects. We evalu...
Finally, smaller prostate volume (PV), as defined by the CTV, was associated with high-volume core involvement (70 cc vs. 79 cc, p < 0.0001). There was no significant difference in high-volume core involvement based on patient age or initial PSA, analyzed either as a continuous or ...
aMonitoring with PSA after treatment for prostate cancer is a mainstay of clinical practice, although the clinical utility of PSA is variable and depends on the disease stage of the indi-vidual patient. As has recently been observed, the lack of high quality information and paucity of clinical...
1 In 2012, the US Preventive Services Task Force recommended against routine prostate-specific antigen (PSA) screening owing to risk of overdiagnosis of clinically insignificant prostate cancer. Consequently, there has been a decrease in indolent, localized disease, but a concordant increase of ...
2 The study’s eligible patients had clinically localized prostate cancer with clinical T1c to T3b disease that would be classified as intermediate or high risk by NCCN, with a PSA level less than 100 ng/mL. Men were randomized to receive 4 or 28 months of ADT. The minimum allowable ...
PSMA expression and CD8+ T-cell infiltration in prostate tissue samples were compared with Wilcoxon rank-sum test [46]. When patients were dichotomised (high/high versus remaining), comparisons to clinical parameters (BCR, surgical margin status, pre-surgery PSA, CAPRA-S risk Score, T-stage ...
Among men with elevated prostate-specific antigen (PSA) but no CaP, the mortality rates were slightly lower, and fewer differences in comorbidities and medication use were noted compared to men without elevated PSA. Many prevalent comorbidities and medications were consistent across groups and are ...